277 related articles for article (PubMed ID: 29527701)
1. Identification of an IL-1-induced gene expression pattern in AR
Thomas-Jardin SE; Kanchwala MS; Jacob J; Merchant S; Meade RK; Gahnim NM; Nawas AF; Xing C; Delk NA
Prostate; 2018 Jun; 78(8):595-606. PubMed ID: 29527701
[TBL] [Abstract][Full Text] [Related]
2. IL-1β induces p62/SQSTM1 and represses androgen receptor expression in prostate cancer cells.
Chang MA; Patel V; Gwede M; Morgado M; Tomasevich K; Fong EL; Farach-Carson MC; Delk NA
J Cell Biochem; 2014 Dec; 115(12):2188-97. PubMed ID: 25103771
[TBL] [Abstract][Full Text] [Related]
3. RELA is sufficient to mediate interleukin-1 repression of androgen receptor expression and activity in an LNCaP disease progression model.
Thomas-Jardin SE; Dahl H; Kanchwala MS; Ha F; Jacob J; Soundharrajan R; Bautista M; Nawas AF; Robichaux D; Mistry R; Anunobi V; Xing C; Delk NA
Prostate; 2020 Feb; 80(2):133-145. PubMed ID: 31730277
[TBL] [Abstract][Full Text] [Related]
4. Chronic IL-1 exposure drives LNCaP cells to evolve androgen and AR independence.
Dahl HC; Kanchwala M; Thomas-Jardin SE; Sandhu A; Kanumuri P; Nawas AF; Xing C; Lin C; Frigo DE; Delk NA
PLoS One; 2020; 15(12):e0242970. PubMed ID: 33326447
[TBL] [Abstract][Full Text] [Related]
5. IL-1-conferred gene expression pattern in ERα
Nawas AF; Kanchwala M; Thomas-Jardin SE; Dahl H; Daescu K; Bautista M; Anunobi V; Wong A; Meade R; Mistry R; Ghatwai N; Bayerl F; Xing C; Delk NA
BMC Cancer; 2020 Jan; 20(1):46. PubMed ID: 31959131
[TBL] [Abstract][Full Text] [Related]
6. Chronic IL-1 Exposed AR
Thomas-Jardin SE; Kanchwala MS; Dahl H; Liu V; Ahuja R; Soundharrajan R; Roos N; Diep S; Sandhu A; Xing C; Delk NA
J Cell Signal; 2021 Dec; 2(4):248-260. PubMed ID: 34988553
[TBL] [Abstract][Full Text] [Related]
7. Androgen receptor as a regulator of ZEB2 expression and its implications in epithelial-to-mesenchymal transition in prostate cancer.
Jacob S; Nayak S; Fernandes G; Barai RS; Menon S; Chaudhari UK; Kholkute SD; Sachdeva G
Endocr Relat Cancer; 2014 Jun; 21(3):473-86. PubMed ID: 24812058
[TBL] [Abstract][Full Text] [Related]
8. Interleukin-4 in patients with prostate cancer.
Takeshi U; Sadar MD; Suzuki H; Akakura K; Sakamoto S; Shimbo M; Suyama T; Imamoto T; Komiya A; Yukio N; Ichikawa T
Anticancer Res; 2005; 25(6C):4595-8. PubMed ID: 16334148
[TBL] [Abstract][Full Text] [Related]
9. In vitro modulation of tumor progression-associated properties of hormone refractory prostate carcinoma cell lines by cytokines.
Sokoloff MH; Tso CL; Kaboo R; Taneja S; Pang S; deKernion JB; Belldegrun AS
Cancer; 1996 May; 77(9):1862-72. PubMed ID: 8646686
[TBL] [Abstract][Full Text] [Related]
10. Transcriptional regulation of the androgen signaling pathway by the Wilms' tumor suppressor gene WT1.
Zaia A; Fraizer GC; Piantanelli L; Saunders GF
Anticancer Res; 2001; 21(1A):1-10. PubMed ID: 11299720
[TBL] [Abstract][Full Text] [Related]
11. Identification of novel androgen receptor target genes in prostate cancer.
Jariwala U; Prescott J; Jia L; Barski A; Pregizer S; Cogan JP; Arasheben A; Tilley WD; Scher HI; Gerald WL; Buchanan G; Coetzee GA; Frenkel B
Mol Cancer; 2007 Jun; 6():39. PubMed ID: 17553165
[TBL] [Abstract][Full Text] [Related]
12. Prostate androgen-regulated gene: a novel potential target for androgen-independent prostate cancer therapy.
Xu XF; Zhou SW; Zhang X; Ye ZQ; Zhang JH; Ma X; Zheng T; Li HZ
Asian J Androl; 2006 Jul; 8(4):455-62. PubMed ID: 16763722
[TBL] [Abstract][Full Text] [Related]
13. Expression profiles and functional associations of endogenous androgen receptor and caveolin-1 in prostate cancer cell lines.
Bennett NC; Hooper JD; Johnson DW; Gobe GC
Prostate; 2014 May; 74(5):478-87. PubMed ID: 24375805
[TBL] [Abstract][Full Text] [Related]
14. Identification of mu-crystallin as an androgen-regulated gene in human prostate cancer.
Malinowska K; Cavarretta IT; Susani M; Wrulich OA; Uberall F; Kenner L; Culig Z
Prostate; 2009 Jul; 69(10):1109-18. PubMed ID: 19353593
[TBL] [Abstract][Full Text] [Related]
15. Cooperation among heterogeneous prostate cancer cells in the bone metastatic niche.
Shahriari K; Shen F; Worrede-Mahdi A; Liu Q; Gong Y; Garcia FU; Fatatis A
Oncogene; 2017 May; 36(20):2846-2856. PubMed ID: 27991924
[TBL] [Abstract][Full Text] [Related]
16. Interleukin-6 induces VEGF secretion from prostate cancer cells in a manner independent of androgen receptor activation.
Ishii K; Sasaki T; Iguchi K; Kajiwara S; Kato M; Kanda H; Hirokawa Y; Arima K; Mizokami A; Sugimura Y
Prostate; 2018 Aug; 78(11):849-856. PubMed ID: 29707793
[TBL] [Abstract][Full Text] [Related]
17. Sodium selenite inhibits interleukin-6-mediated androgen receptor activation in prostate cancer cells via upregulation of c-Jun.
Gazi MH; Gong A; Donkena KV; Young CY
Clin Chim Acta; 2007 May; 380(1-2):145-50. PubMed ID: 17346688
[TBL] [Abstract][Full Text] [Related]
18. Interleukin-6 undergoes transition from growth inhibitor associated with neuroendocrine differentiation to stimulator accompanied by androgen receptor activation during LNCaP prostate cancer cell progression.
Lee SO; Chun JY; Nadiminty N; Lou W; Gao AC
Prostate; 2007 May; 67(7):764-73. PubMed ID: 17373716
[TBL] [Abstract][Full Text] [Related]
19. The AR/NCOA1 axis regulates prostate cancer migration by involvement of PRKD1.
Luef B; Handle F; Kharaishvili G; Hager M; Rainer J; Janetschek G; Hruby S; Englberger C; Bouchal J; Santer FR; Culig Z
Endocr Relat Cancer; 2016 Jun; 23(6):495-508. PubMed ID: 27255895
[TBL] [Abstract][Full Text] [Related]
20. Regulation of prostate cancer cell migration toward bone marrow stromal cell-conditioned medium by Wnt5a signaling.
Jin F; Qu X; Fan Q; Wang L; Tang T; Hao Y; Dai K
Mol Med Rep; 2013 Nov; 8(5):1486-92. PubMed ID: 24064566
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
